INVESTORS
2019-04-26MMMM D, YYYY
First Quarter 2019 Results
At a glance
2019-04-30MMMM D, YYYY
Annual General Meeting 2019
Find all information about the Annual General Meeting 2019
Stock market
Annual Report on Form 20-F 2018
Contact the Investor Relations team
54 rue La Boétie
75008 Paris FRANCE
France +33 (0)1 53 77 45 45 • ir@sanofi.com
United States +1 908 981 5560
In-depth reading
New franchise Rare Blood Disorders
In 2018, Sanofi created a leading platform in Rare Blood Disorders through a series of three strategic deals: we obtained global rights for fitusiran, acquired Bioverativ and Ablynx. These operations should expand Sanofi’s presence in Specialty Care and further strengthen our Research & Development pipeline.
The digital revolution
2018 Integrated Report
Quick links
About Sanofi
Individual shareholders
Access your dedicated section
Shareholder Handbook 2019
SANOFI IR The Investor Relations app
SANOFI IR provides financial information with direct access to key news, events, publications and a dedicated section for individual shareholders
